Multi-organ denervation
The system addresses the challenge of varying anatomical responses by automatically selecting therapy programs based on organ type, enhancing the efficacy of neuromodulation therapies.
Patent Information
- Application Number
- PCT/EP2026/062982
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-05
- Publication Date
- 2026-11-12
AI Technical Summary
Existing neuromodulation therapies face challenges due to varying anatomical responses in different regions, such as renal and hepatic areas, due to differences in tissue properties, which affect the efficacy of energy delivery.
A system that uses imaging and processing circuitry to automatically determine the organ type based on anatomical images, selecting appropriate therapy programs for renal or hepatic regions, thereby optimizing neuromodulation energy delivery.
Enhances the precision and effectiveness of neuromodulation therapies by ensuring appropriate energy delivery based on the specific organ type, improving treatment outcomes.
Smart Images

Figure EP2026062982_12112026_PF_FP_ABST
Abstract
Description
A0013531W001MULTI-ORGAN DENERVATION
[0001] This application claims the benefit of U.S. Provisional Patent Application Serial No. 63 / 802,060, filed May 8, 2025, the entire content of which is incorporated herein by reference.TECHNICAL FIELD
[0002] The present disclosure generally relates to multi-organ denervation, for example, during neuromodulation therapy.BACKGROUND
[0003] A denervation procedure may include ablating target nerves, for example, by delivering ablative energy to a target site via a catheter. For example, renal denervation may include ablating renal nerves, hepatic nerves, or other nerves. Multi-organ denervation involves ablating nerves at different locations via energy delivered through different blood vessels. For example, radiofrequency energy may be delivered through walls of different arteries (e.g., renal arteries or the common hepatic artery) to denervate target (e.g., a kidney or the liver) organs by nerve ablationSUMMARY
[0004] In general, the present disclosure describes techniques (e.g., systems and methods) for multi-organ denervation, for example, during neuromodulation therapy.
[0005] Different anatomical regions may exhibit differences in response to therapy (e.g., neuromodulation therapy), because of differences in tissue properties (for example, thermal conductivity, electrical conductivity, chemical diffusivity, gross density, or extent of innervation or vascularization). Thus, different anatomical regions may respond differently to neuromodulation energy delivered in course of therapy. Accordingly, different therapy parameters may be beneficial for different anatomical regions, for example, regions associated with different organs, such as a renal region (kidney) or a hepatic region (liver). A clinician may introduce a catheter including a therapy delivery element in a blood vessel, and deliver neuromodulation therapy through the therapy delivery element. Techniques according to the present disclosure may be used to verify the anatomical location at which the catheter is positioned (for example, an organ type associated with anatomical location or the bloodA0013531W001vessel), and then select a therapy program for delivering therapy based on the anatomical location (e.g., based on the organ type).
[0006] For example, a clinician may introduce a catheter including the therapy delivery element in a blood vessel, and image the catheter and a surrounding anatomical region.Techniques according to the present disclosure may be used to analyze one or more images of the anatomical region in which the catheter is located, and determine the organ type associated with the anatomical region based on the one or more images. Techniques according to the present disclosure may further be used to select a therapy program based on the organ type. For example, if the determined organ type is renal type, a renal therapy program may be selected to deliver therapy at the anatomical region through the therapy delivery element. Similarly, if the determined organ type is hepatic type, a hepatic therapy program may be selected to deliver therapy at the anatomical region through the therapy delivery element. Thus, the clinician may position or re-position the catheter at one or more anatomical regions (e.g., for a single organ or multi-organ therapy), and appropriate therapy may be delivered based on a present location of the catheter.
[0007] In some examples, an example system includes processing circuitry configured to receive an image signal indicative of at least one image of an anatomical region in which a catheter is positioned. The processing circuitry may be further configured to determine, based on the image signal, an organ type associated with the anatomical region. The processing circuitry may be further configured to select, based on the organ type, a therapy program. The processing circuitry may be further configured to perform at least one action based on the therapy program.
[0008] In some examples, an example technique includes receiving, by processing circuitry, an image signal indicative of at least one image of an anatomical region in which a catheter is positioned. The technique may further include determining, by the processing circuitry, based on the image signal, an organ type associated with the anatomical region. The technique may further include selecting, by the processing circuitry, based on the organ type, a therapy program. The technique may further include performing, by the processing circuitry, at least one action based on the therapy program.
[0009] Further disclosed herein is a system that includes processing circuitry being configured to receive an image signal indicative of at least one image of an anatomical region in which a catheter is positioned, wherein the processing circuitry may be further configured to determine, based on the image signal, an organ type associated with the anatomical region, wherein the processing circuitry may be further configured to select, based on the organ type,A0013531W001a therapy program, and wherein the processing circuitry may be further configured to perform at least one action based on the therapy program.
[0010] The details of one or more examples of the techniques of this disclosure are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the techniques will be apparent from the description and drawings, and from the claims.BRIEF DESCRIPTION OF DRAWINGS
[0011] FIG. l is a diagram illustrating an example system including a neuromodulation system, and a computing device.
[0012] FIG. 2 is a block diagram illustrating an example configuration of the computing device of FIG. 1.
[0013] FIG. 3 is a schematic diagram illustrating a scheme for determining an organ type based on at least one image indicative of a take-off angle of a blood vessels.
[0014] FIG. 4 is a schematic diagram illustrating a scheme for determining an organ type based on at least one image indicative of a presence or absence of an organ outline.
[0015] FIG. 5 is a schematic diagram illustrating a scheme for using a machine learning model to determine an organ type based on at least one image.
[0016] FIG. 6 is a flow diagram illustrating an example technique for neuromodulation.
[0017] FIG. 7 illustrates an example technique for accessing a renal artery and modulating renal nerves with a neuromodulation catheter in accordance with some examples of the present disclosure.
[0018] FIG. 8 is a conceptual illustration of an example sympathetic nervous system (SNS) illustrating how the brain communicates with the body via the SNS.
[0019] FIG. 9 is an enlarged anatomic view of nerves innervating a left kidney to form the renal plexus surrounding the left renal artery.
[0020] FIG. 10 is an anatomic view of a human body depicting neural efferent and afferent communication between the brain and kidneys.
[0021] FIG. 11 is a conceptual view of a human body depicting neural efferent and afferent communication between the brain and kidneys.
[0022] FIG. 12 is an anatomic view of the arterial vasculature of a human.
[0023] FIG. 13 is an anatomic view of the venous vasculature of a human.A0013531W001DETAILED DESCRIPTION
[0024] The present disclosure describes techniques (e.g., systems and methods) for multiorgan denervation.
[0025] As used herein, the terms “distal” and “proximal” define a position or direction with respect to the treating clinician or clinician’s control device (e.g., a handle assembly). “Distal” or “distally” can refer to a position distant from or in a direction away from the clinician or clinician’s control device. “Proximal” and “proximally” can refer to a position near or in a direction towards the clinician or clinician’s control device.
[0026] A neuromodulation system may include a catheter including a plurality of therapy delivery elements used to deliver therapy. For example, the neuromodulation system may include a generator electrically coupled to the catheter and configured to deliver neuromodulation energy through the therapy delivery elements into an anatomical region of the patient for a predetermined period of time. In some examples, the therapy includes denervation, the therapy delivery elements include electrodes, and the neuromodulation system is configured to deliver ablative energy through the electrodes. The system may monitor parameters such as tissue temperature and impedance of the patient. The generator may control one or more therapy parameters, for example, initiating therapy, ramping or stepping up therapy intensity, ramping or stepping down therapy intensity, or pausing or stopping therapy, based on an average tissue temperature.
[0027] However, variances in temperature feedback to neuromodulation therapy between different blood vessels or organ types (e.g., the renal arteries and common hepatic artery) may impact neuromodulation parameters, and thus the overall effect of the therapy. Accordingly, one or more therapy parameters may be adjusted based on a target region or location, for example, using different therapy parameters for a renal region, a hepatic region, or other regions or locations in the body. Thus, different neuromodulation programs may be used by a single generator to deliver different neuromodulation therapies (e.g., a renal program and a hepatic program). Additionally, a neuromodulation system may automatically adopt a neuromodulation program depending on where the catheter is placed within the body.
[0028] In particular, instead of requiring a clinician to select a neuromodulation program, the system (e.g., the generator or a separate computing device or processing circuitry) may automatically select an appropriate program, and possibly with clinician approval (e.g., provide recommendation of the appropriate program for confirmation). For example, one or more images of an anatomical region (in which a neuromodulation catheter is positioned) may be used to detect what vessel the catheter is placed in (e.g., the organ type associated with theA0013531W001vessel) at any one time. In some examples, a neuromodulation system directly communicates with a generator to select or set an appropriate therapy program based on the detected vessel or organ type.
[0029] In some examples, a single device (e.g., a radiofrequency generator) is configured to analyze images (e.g., fluoroscopic images or contrast images) and act as a generator for delivering neuromodulation energy. Thus, a generator (e.g., a radiofrequency ablation generator) may be equipped with software and hardware capability to read and interpret images to determine what vessel the catheter is in, and select or set an appropriate therapy program. In other examples, an additional computing device may analyze the images and select or set the appropriate therapy program, and the computing device may control the generator to deliver therapy based on the selected therapy program. In still further examples, a digital surgery platform may be used as an interpreter / instructor between an imaging system (e.g., a fluoroscopic system) and a neuromodulation system (e.g., a radiofrequency ablation system). The images may get analyzed by the digital surgery unit to determine what vessel the catheter is in, and in turn the digital surgery unit may send a command to the neuromodulation system regarding the therapy program to be used.
[0030] As an example, a process flow may include: a clinician advancing a catheter to a target therapy location; the system prompting the clinician to capture an image (e.g., a fluoroscopic image) of a catheter position; the clinician capturing an image and confirming a prompt for the catheter position; the system interpreting the catheter location based on the image; the system optionally receiving a confirmation from a clinician that the determined catheter location is correct; the system selecting an appropriate therapy program based on the catheter location (possibly with clinician approval); and the system activating delivery of therapy based on the therapy program.
[0031] Certain anatomical images (e.g., fluoroscopic images) may indicate blood vessels and other anatomical features, but may not permit nerve visualization or indication of nerve location. Thus, a detection of a blood vessel known to be associated with a predetermined organ type may be indicative of a presence of nerves associated with that organ type, even if the nerves are not directly indicated by the anatomical images. In some examples, the system may distinguish between different blood vessels (e.g., renal vs. hepatic). In some examples, the system may not specifically detect a particular vessel type, and may only distinguish between renal and hepatic vessels, or between surrounding or neighboring organs or structures visible in anatomical images to aid in detection of an anatomical location at which a catheter is positioned. In this way, the system may be used to analyze images and deliverA0013531W001neuromodulation therapy to certain nerve types (e.g., renal type or hepatic type) even though the nerves themselves may not be distinguishable or perceptible in the images.
[0032] The system may distinguish the anatomy based on one or more anatomical features, and may combine different techniques for detecting features. For example, the system may compare take-off geometry (e.g., take-off angles) of a vessel relative to an aorta (or some other vessel or trunk). Renal arteries have a lateral take-off from the aorta, sometimes slightly dorsal. The take-off may be determined as an angle or orientation between a branch and a main vessel (or between a sub-branch and a branch), for example, at a starting point of the branch, or where the branch is coupled to the main vessel (e.g., the aorta). Thus, a branch that extends laterally away from a main vessel at the point where the branch is coupled to the vessel has a lateral take-off. Similarly, a branch that extends dorsally away from the main vessel at the point where the branch is coupled to the vessel has a dorsal takeoff, while a branch that extends ventrally away from the main vessel at the point where the branch is coupled to the vessel has a ventral take-off. The hepatic artery originates from the celiac trunk which has a ventral take-off from the aorta. Thus, the system may assess images of a target vessel at different projection angles (e.g., two angles) to determine whether the vessel has a lateral or ventral take-off, and identify the vessel as renal type or celiac (hepatic). In some examples, the system may distinguish kidneys from a liver portion through contrast filling. When taking fluoroscopic images of the renal arteries, the contrast agent fills down into the kidney and creates an evident shadow outline of the organ. In contrast, when taking fluoroscopic images of the hepatic artery, the contrast agent gets dispersed into the multiple branching arteries (left / right hepatic, splenic, gastroduodenal) rather than into a single organ. The system can thus use fluoroscopic images to identify the presence or absence of a kidney (e.g., indicated by a presence of a kidney outline in a fluoroscopic image) and therefore determine whether the vessel is renal type or hepatic.
[0033] Thus, instead of requiring a clinician to analyze images and determine an appropriate therapy program, techniques according to the present disclosure may be used to automate image analysis or therapy selection, or to provide further confirmatory assessment in addition to a clinician’s assessment. Accordingly, an appropriate therapy program may be used to deliver therapy based on an organ type determined by imaging. In some examples, artificial intelligence or machine learning may be used to analyze one or more images, determine vessel or organ type, and / or select a therapy program.
[0034] While examples of techniques according to the present disclosure are described with reference to certain organs such as the kidneys and the liver, any other type of organsA0013531W001may be involved. Further, while examples of techniques according to the present disclosure are described with reference to neuromodulation (e.g., denervation or ablation) therapy, any other type of therapy may be involved.
[0035] FIG. 1 is a diagram illustrating an example system 10 including a catheter 12 configured to deliver neuromodulation therapy, a computing device 16, and a medical device 18. In FIG. 1, catheter 12 is in a relatively low profile configuration. Catheter 12 is also referred to as neuromodulation catheter 12.
[0036] Computing device 16 may be configured to send a control signal to medical device 18 or otherwise control the operation of one or both of catheter 12 or medical device 18. In some examples, the control signal sent by computing device 16 to medical device 18 is configured to cause medical device 18 to, based on the control signal received from computing device 16, generate a therapy signal. Medical device 18 may generate the therapy signal sent to catheter 12 to cause catheter 12 to deliver neuromodulation therapy. For example, the neuromodulation therapy may include renal neuromodulation, hepatic neuromodulation, or any other neuromodulation therapy, for a neuromodulation procedure. In some examples, the neuromodulation therapy is configured to reduce a blood pressure in a patient.
[0037] Medical device 18 may be configured to generate a signal including the therapy signal configured to be delivered by catheter 12. For example, medical device 18 may include a control circuitry 40 and a therapy generation circuitry 42, and control circuitry 40 may be configured to control therapy generation circuitry 42 to generate the therapy signal. The therapy signal may be configured to cause catheter 12 to deliver neuromodulation therapy, for example, to reduce a blood pressure in the patient.
[0038] System 10 may further include an imaging system 44 configured to image an anatomical region in which catheter 12 is introduced. Imaging system 44 may include any suitable imaging system, for example, a fluoroscopic imaging system, a computed tomography (CT) imaging system, a magnetic resonance imaging (MRI) system, an ultrasound system, or any other system. In some examples, imaging system 44 is configured to generate at least one image (e.g., a plurality of images) during or after introduction of contrast agent in the anatomical region (e.g., through blood vessels). In some examples, imaging system 44 is configured to generate a plurality of images showing different views or perspectives of the anatomical region.
[0039] System 10 may be configured to determine a catheter location in a patient, for example, based on one or more images generated by imaging system 44. For example,A0013531W001computing device 16, or control circuitry 40 of medical device 18, may be configured to determine the catheter location. In some examples, computing device 16 is configured to receive an image signal (e.g., from imaging system 44) indicative of at least one image of an anatomical region in which catheter 12 is positioned. Computing device 16 may be further configured to determine, based on the image signal, an organ type associated with the anatomical region. Computing device 16 may be further configured to select, based on the organ type, a therapy program. Computing device 16 may be further configured to perform at least one action based on the therapy program. While examples of configuration of computing device 16 (e.g., processing circuitry of computing device 16) are described with respect to FIG. 2, it is understood that functions may be shared or divided between computing device 16 and control circuitry 40.
[0040] Catheter 12 includes a handle 20 and an elongate body 22 attached to handle 20. That is, handle 20 is positioned at a proximal portion of elongate body 22. Elongate body 22 extends in a direction along a longitudinal axis L of catheter 12. Elongate body 22 may have any suitable outer diameter, and the diameter can be constant along the length of elongate body 22 or may vary along the length of elongate body 22. In some examples, elongate body 22 may be 2, 3, 4, 5, 6, or 7 French or another suitable size. Elongate body 22 extends along a central longitudinal axis L, and includes a distal catheter portion 22A and a proximal catheter portion 22B. Distal catheter portion 22A includes an expandable portion 24.
[0041] Expandable portion 24 is configured to transform from a relatively low-profile configuration (shown in FIG. 1) to a radially expanded deployed configuration (not shown). Elongate body 22 is configured to expand from the relatively low-profile configuration (shown in FIG. 1) to an expanded configuration, such as a spiral, loop, or helical configuration.
[0042] Catheter 12 further includes a therapy delivery element 26 disposed on elongate body 24. Therapy delivery element 26 is configured to deliver neuromodulation therapy. For example, therapy delivery element 26 may include one or more of an electrode, a thermal probe, a cryogenic probe, a microwave transducer, an ultrasound transducer, or a chemical denervation agent source. In some examples, therapy delivery element 26 includes at least one electrode configured to deliver an ablation signal (e.g., RF energy, microwave energy, or the like). For example, control circuitry 40 may be configured to control therapy generation circuitry 42 to generate the therapy signal configured to be delivered by therapy delivery element 26.A0013531W001
[0043] Therapy generation circuitry 42 may be configured to deliver therapy to tissue of a patient via therapy delivery element 26, for example, to modulate a target nerve of the patient. For example, therapy delivery element 26 may be coupled to therapy generation circuitry 42, and therapy generation circuitry 42 may deliver a therapy signal to tissue, or to a target site via therapy delivery element 26. Catheter 12 may thus deliver denervation therapy via therapy delivery element 26, and computing device 16 or control circuitry 40 may control catheter 12 to deliver denervation therapy.
[0044] Therapy delivery element 26 may have any suitable shape, size, or form. In some examples, each therapy delivery element 26 consists of one electrode. In some examples, catheter 12 includes a plurality of therapy delivery elements 26 disposed along elongate body 24, for example, aligned with a direction along longitudinal axis L of catheter 12. Although FIG. 1 illustrates four therapy delivery elements 26, in other examples, catheter 12 may include one, two, three, five, or more therapy delivery elements 26. In some examples, at least one therapy delivery element 26 includes gold, iridium oxide, or platinum iridium alloy.
[0045] At least one electrode of therapy delivery element 26 may be coupled to a respective thermocouple. For example, control circuitry 40 may sense a respective temperature of the at least one electrode via the thermocouple. In some examples, control circuitry 40 may be configured to terminate neuromodulation therapy in response to a temperature sensed by the thermocouple, for example, to avoid excessive heating of catheter 12 or neighboring tissue.
[0046] Catheter 12 may be connected to control circuitry 40 (e.g., a therapy delivery device or within medical device 18). Control circuitry 40 may include control circuitry and therapy source (for example, an electrical signal generator, or the like; not shown in FIG. 1) via at least one electrical conductor and / or at least one lumen defined by handle 20 and elongate body 22. Control circuitry 40, as well as other processors, processing circuitry, controllers, control circuitry, and the like, described herein, may include any combination of integrated circuitry, discrete logic circuity, analog circuitry, such as one or more microprocessors, digital signal processors (DSPs), application specific integrated circuits (ASICs), or field-programmable gate arrays (FPGAs). In some examples, control circuitry 40 includes multiple components, such as any combination of one or more microprocessors, one or more DSPs, one or more ASICs, or one or more FPGAs, as well as other discrete or integrated logic circuitry, and / or analog circuitry.
[0047] Control circuitry 40 may be communicatively coupled to a memory that may store program instructions, such as software, which may include one or more program modules,A0013531W001which are executable by control circuitry 40. When executed by control circuitry 40, such program instructions may cause control circuitry 40 to provide the functionality ascribed to control circuitry 40herein. The program instructions may be embodied in software and / or firmware. The memory, as well as other memories described herein, may include any volatile, non-volatile, magnetic, optical, or electrical media, such as a random access memory (RAM), read-only memory (ROM), non-volatile RAM (NVRAM), electrically-erasable programmable ROM (EEPROM), flash memory, or any other digital media. Control circuitry 40 and the memory may be in a common housing, or be physically separate from each other.
[0048] Distal catheter portion 22A of catheter 12 is configured to be advanced within an anatomical lumen of a human patient to locate at least one electrode of therapy delivery element 26 at a target tissue site within or otherwise proximate to the anatomical lumen. For example, catheter 12 may be configured to position distal catheter portion 22A within a blood vessel, a ureter, a urethra, a duct, an airway, or another naturally occurring lumen within the human body. The examples described herein focus on the anatomical lumen being a blood vessel, such as a renal vessel, but it will be understood that similar techniques may be used with other anatomical lumens.
[0049] Catheter 12 can be configured for delivery to a target tissue site within vasculature of a patient via a guide member, which can include, for example, one or more of a guidewire or an outer sheath. In certain examples, intravascular delivery of distal catheter portion 22A includes percutaneously inserting a guidewire (not shown in FIG. 1) into a vessel of a patient and moving at least elongate body 22 (for example, at least expandable portion 24) along the guidewire until expandable portion 24 reaches a target tissue site (for example, a renal artery). For example, distal catheter portion 22A of elongate body 22 (e.g., expandable portion 24) may define a lumen configured to receive a guidewire for delivery of distal catheter portion to a target tissue site using over-the-wire (OTW) or rapid exchange (RX) techniques. In other examples, catheter 12 can be a steerable or non-steerable device configured for use without a guidewire. In still other examples, catheter 12 can be configured for delivery via an inner lumen of a guide member, for example, a guide catheter, an outer sheath (not shown in FIG.1), or other guide device.
[0050] A distal end of elongate body 22 defines distal tip 28. Distal tip 28 is configured to facilitate navigation of distal catheter portion 22A within the vasculature of the patient to a blood vessel. In some examples, distal tip 28 may be atraumatic, for example, to resist or avoid puncturing a vessel of a blood vessel during navigation of distal catheter portion 22A within the blood vessel.A0013531W001
[0051] In the example illustrated in FIG. 1, catheter 12 is in a relatively low-profile delivery configuration, in which distal catheter portion 22A defines a relatively smaller radial extent (a relatively low-profile, such as a relatively linear configuration) relative to expanded (also referred to as a radially expanded and / or deployed) configuration 12A in which expandable portion 24 of distal catheter portion 22A defines a relatively larger radial extent. In some examples, the radial extent is measured in a direction orthogonal to central longitudinal axis L. Distal catheter portion 22A may be delivered through vasculature of the patient to the target tissue site in the low-profile configuration. In some examples, expandable portion 24 is configured to self-expand within a blood vessel of a patient, e.g., via a shape-memory element (e.g., a shape memory tube or a hollow helical strand) of elongate body 22. In some examples, expandable portion 24 (e.g., elongate body 22) extends along a straight line aligned with longitudinal axis L in the relatively low-profile configuration shown in FIG. 1. Expandable portion 24 may be constrained or restrained in the low-profile configuration by a guide member. The clinician may retract the guide member proximally relative to expandable portion 24 to un-constrain expandable portion 24 and cause or allow expandable portion 24 to transform from the low-profile configuration to an expanded configuration. Thus, expandable portion 24 may be configured to radially expand to the expanded configuration.
[0052] In some examples, in an expanded configuration, expandable portion 24 defines a loop, a helix, or a spiral shape, or a basket, or a stent-like configuration. In the expanded configuration, expandable portion 24 is configured to position one or more therapy delivery elements 26 near a vessel wall, for example, in apposition with the vessel wall.
[0053] In some examples, expandable portion 24 may be expanded or may self-expand as a result of proximal retraction of a guide member from distal catheter portion 22A. The clinician may retract the guide member to a location along distal catheter portion 22A proximal to expandable portion 24 to cause or allow expandable portion 24 to expand. In the expanded configuration, expandable portion 24 may place at least one therapy delivery element 26 at a first location relative to the vessel wall, for example, corresponding to a first rotational location. A clinician may control a therapy delivery device to deliver, provide, or facilitate neuromodulation therapy at the target tissue site, for example, through the vessel wall at the target tissue site to target tissue adjacent to the blood vessel. The neuromodulation therapy may include, but is not limited to, radiofrequency (RF) energy, microwave energy, or the like.A0013531W001
[0054] The clinician may rotate handle 20, or otherwise proximal portion 22B, to apply a torque to distal portion 22A and cause expandable portion 24 to rotate about central longitudinal axis L from the first rotational location to a second rotational location. For example, the application of torque from handle 20 or proximal portion 22B to expandable portion 24 may cause expandable portion 24 to rotate about longitudinal axis L, for example, in a same direction as the torque. The clinician may control system 10 to deliver ablation therapy or stimulation at the second rotational location, or after further successive rotational locations of expandable portion 24.
[0055] System 10 and / or catheter 12 may be used to deliver neuromodulation therapy (e.g., ablation) according to any appropriate scheme. For example, computing device 16 or control circuitry 40 may control catheter 12 to deliver a neuromodulation therapy. For example, computing device 16 may be configured to generate and send a control signal to control circuitry 40, and control circuitry 40 may be configured to generate, based on the control signal, an electrical signal sent to catheter 12.
[0056] FIG. 2 is a block diagram illustrating an example configuration of computing device 16 of FIG. 1. In some examples, medical device 18 or control circuitry 40 may include computing device 16, or include one or more components described with reference to computing device 16, or otherwise perform functions described with reference to computing device 16. Computing device 16 may include a workstation, a tablet computer, a laptop computer, or a desktop computer. Computing device 16 or a similar computing device may be used to control any example system or catheter according to the present disclosure.
[0057] As shown in the example of FIG. 2, computing device 16 includes processing circuitry 170, storage device 172, communication circuitry 174, and a user interface 176. While computing device 16 may be a stand-alone device as shown in FIG. 2, in other examples, computing device 16 may be any component or system that includes processing circuitry or other suitable computing environment for executing software instructions and, for example, need not necessarily include one or more elements shown in FIG. 2 (e.g., in some examples components such as storage device 172 may not be co-located or in the same housing or structure as other components).
[0058] Processing circuitry 170, in some examples, is configured to implement functionality and / or process instructions for execution within at least one computing device 16. For example, processing circuitry 170 may be capable of processing instructions, including at least one application 180, stored in storage device 172. Examples of processing circuitry 170, as well as other processors, processing circuitry, controllers, control circuitry,A0013531W001and the like, described herein, may include any combination of integrated circuitry, discrete logic circuitry, analog circuitry, such as one or more microprocessors, digital signal processors (DSPs), application specific integrated circuits (ASICs), or field-programmable gate arrays (FPGAs). In some examples, processing circuitry 170 includes multiple components, such as any combination of one or more microprocessors, one or more DSPs, one or more ASICs, or one or more FPGAs, as well as other discrete or integrated logic circuitry, and / or analog circuitry.
[0059] Storage device 172 (which can also be referred to as a memory) may be configured to store information within computing device 16, including at least one application 180 and data 190. Storage device 172, in some examples, is a computer-readable storage medium. In some examples, storage device 172 includes a temporary memory or a volatile memory. Storage device 172, in one example, is used by at least one application 180 running on computing device 16 to temporarily store information during program execution. Storage device 172, in some examples, also includes one or more memories configured for long-term storage of information, e.g., including non-volatile storage elements. Examples of such nonvolatile storage elements include any volatile, non-volatile, magnetic, optical, or electrical media, such as a random access memory (RAM), read-only memory (ROM), non-volatile RAM (NVRAM), electrically-erasable programmable ROM (EEPROM), flash memory, or any other digital media.
[0060] Computing device 16 utilizes communication circuitry 174 to communicate with other devices, such as catheter 12, control circuitry 40, other computing devices, and system 10 of FIG. 1. Communication circuitry 174 may include a network interface card, such as an Ethernet card, an optical transceiver, a radio frequency transceiver, or any other type of device that can send and receive information. Other examples of such network interfaces may include 3G, 4G, 5G, and WiFi radios.
[0061] Computing device 16 may include a user interface 176. User interface 176 may be configured to provide output to a user using tactile, audio, or video stimuli and receive input from a user through tactile, audio, or video feedback. User interface 176 may include, as examples, a presence-sensitive display, a mouse, a keyboard, a voice responsive system, video camera, microphone, or any other type of device for detecting a command from a user, a sound card, a video graphics adapter card, or any other type of device for converting a signal into an appropriate form understandable to humans or machines, a speaker, a display device, such as, but not limited to, cathode ray tube (CRT) monitor, a liquid crystal display (LCD), orA0013531W001any other type of device that can generate intelligible output to a user. In some examples, a presence-sensitive display includes a touch-sensitive screen.
[0062] At least one application 180 executable by processing circuitry 170 of computing device 16 may include an imaging interface application 182 that may respectively utilize signals sent by imaging system 44 (or other signals indicative of images of an anatomical region). At least one application 180 further may include a neuromodulation interface application 186 that controls delivery of neuromodulation therapy via control circuitry 40 and / or catheter 12.
[0063] Execution of one or both of imaging interface application 182 or neuromodulation interface 186 by processing circuitry 170 configures computing device 16 to interface with system 10 or control circuitry 40 (or catheter 12). For example, imaging interface application 182 configures computing device 16 to communicate with imaging system 44 via communication circuitry 174 and imaging interface application 182 receives a signal indicative of at least one image of an anatomical region in which catheter 12 is positioned. Processing circuitry 170 may store imaging data 192 in storage device 172.
[0064] Processing circuitry 170 may receive a signal from a physiological sensor indicative of a physiological parameter, and store physiological data 194 based on the signal in storage device 172. Physiological parameters may include, but are not limited to, electrical conduction, electrical impedance, tissue response, heat response (e.g., heart rate), or any other physiological parameter that may change as a result of neuromodulation. Processing circuitry 170 may be configured to use physiological data 194 (e.g., in conjunction with imaging data 192) to select or set a therapy program or a therapy parameter. Imaging interface application 182 and / or neuromodulation interface 186 also configures user interface 176 for a user to interact with control circuitry 40 (or catheter 12). One or both of imaging interface application 182 or neuromodulation interface 186 may cause processing circuity 170 and computing device 16 to perform any of the techniques described herein related to neuromodulation by system 10.
[0065] In some examples, processing circuitry 170 is configured to receive an image signal indicative of at least one image of an anatomical region in which a catheter is positioned. The at least one image may include a fluoroscopic image, or any other image such as a CT image, an MRI image, an X-ray image, or an ultrasound image. Processing circuitry 170 may be further configured to determine, based on the image signal, an organ type associated with the anatomical region. For example, the organ type may be selectedA0013531W001from two organ types (e.g., a binary selection such as renal type vs. hepatic), or from three or more organ types.
[0066] Processing circuitry 170 may be further configured to select, based on the organ type, a therapy program. For example, the therapy program may be configured to cause catheter 12 to deliver neuromodulation therapy with therapy parameters (e.g., intensity, duration, ramp, pulsing, or any other parameter) appropriate for nerves associated with the determined organ type. The therapy program is configured to, when delivered via therapy delivery element 26 (or to catheter 12), cause neuromodulation of nerves associated with the organ type at the anatomical region. The neuromodulation may include any suitable effect on nerve activity, for example, attenuation of nerve activity, or termination of nerve activity. In some examples, the therapy program is configured to, when delivered via the therapy delivery element, cause denervation of the nerves associated with the organ type at the anatomical region. Processing circuitry 170 may store therapy data 196 including a plurality of therapy programs, and may select a therapy program from therapy data 196. In other examples, processing circuitry 170 may receive therapy data 196 from an external source, for example, another computing device or database.
[0067] Processing circuitry 170 may be further configured to perform at least one action based on the therapy program (or the organ type). For example, processing circuitry 170 may be configured to perform the at least one action by generating an output, an alert, or an indicator signal indicative of one or both of the organ type or the therapy program.
[0068] In some examples, the at least one image includes at least one fluoroscopic image. For example, the at least one image may include a plurality of fluoroscopic images. The plurality of fluoroscopic images may include respective images representative of one or both of different periods of time (e.g., during or after delivery of contrast agent) or different views or perspectives of the anatomical region. For example, the plurality of fluoroscopic images may include images indicating sequential or progressive migration or diffusion of the contrast agent in the anatomical region (e.g., along stems and / or branches or blood vessels), or different views such as dorsal, ventral, lateral, or any other view.
[0069] In some examples, processing circuitry 170 is further configured to select different neuromodulation programs in response to different determined organ types. For example, processing circuitry 170 may be configured to select a renal neuromodulation program as the therapy program in response to determining that the organ type is a renal type. Processing circuitry 170 may be further configured to select a hepatic neuromodulation program as the therapy program in response to determining that the organ type is a hepatic type. In this way,A0013531W001an appropriate therapy program may be set or selected based on the organ type. In some examples, instead of selecting an overall therapy program, processing circuitry 170 may be configured to set, select, or adjust at least one therapy program parameter (e.g., type of energy delivery, intensity of energy delivery, intermittency of energy delivery, duration of energy delivery, ramping up or ramping down of energy delivery, or spatial pattern of energy delivery).
[0070] In some examples, the organ type is selected from a group consisting of the renal type or the hepatic type. Thus, instead of needing to determine an organ type from any possible type of organs, processing circuitry 170 may be configured to solely distinguish a renal location or renal organ type from a hepatic location or hepatic organ type. For example, such distinguishing between two predetermined organ types may be relatively simpler or more accurate compared to selecting an organ type from a plurality of three or more organ types.
[0071] In some examples, to determine the organ type associated with the anatomical region, processing circuitry 170 is further configured to determine a blood vessel type associated with the anatomical region. For example, the blood vessel type may include a renal artery or a hepatic artery (or any other vessel, e.g., mesenteric artery). In some examples, processing circuitry 170 may be configured to determine the blood vessel type based on one or more geometric aspects, such as vessel diameter, tortuosity, extent of branching, average branch length or diameter, one or more ratios between branch dimensions and trunk dimension, or any other suitable geometric aspect.
[0072] In some examples, to determine the blood vessel type, processing circuitry 170 is configured to determine a take-off geometry of at least one blood vessel from another blood vessel or a trunk (e.g., as described with reference to the scheme of FIG. 3). In some such examples, the image signal is indicative of at least two images differing in an image projection angle. To determine the take-off geometry of the at least one blood vessel from the other blood vessel or the trunk, processing circuitry 170 may be configured to compare the at least two images. For example, processing circuitry 170 may be configured to determine the blood vessel type as renal type in response to determining that the at least one blood vessel has a lateral or slightly dorsal take-off from the aorta. Alternatively, processing circuitry 170 may be configured to determine the blood vessel type as hepatic type in response to determining that the at least one blood vessel has a ventral take-off from the aorta.
[0073] In some examples, the at least one image includes at least one contrast image. In some such examples, to determine the organ type associated with the anatomical region,A0013531W001processing circuitry 170 is further configured to determine a presence of a shadow outline of an organ in the at least one contrast image (as described with reference to the scheme of FIG.4). In some such examples, processing circuitry 170 is configured to determine the organ type as renal type in response to determining that shadow outline is present. Vice versa, processing circuitry 170 may be configured to determine the organ type as hepatic type in response to determining that the shadow outline is absent. In some examples, processing circuitry 170 is configured to compare an intensity of darkness of an organ (i.e., based on more or less blood or contrast in the organ) with a predetermined threshold intensity value or range. For example, the predetermined threshold intensity value or range may be associated with an intensity of a known device or an anatomical reference. Processing circuitry 170 may determine the anatomical region to be associated with a particular organ type in response to determining, based on the comparison, that the measured intensity exceeds the predetermined threshold intensity value or falls within the predetermined threshold intensity range.
[0074] In some examples, medical device 18 includes a neuromodulation generator. In some such examples, the neuromodulation generator is configured to receive the indicator signal from processing circuitry 170. The neuromodulator generator may be further configured to, based on the indicator signal, generate a therapy signal for delivery to neuromodulation catheter 12 configured to deliver neuromodulation therapy. In some examples, the neuromodulation generator includes processing circuitry 170. In some examples, system 10 includes two medical devices 18 (e.g., two generators), each medical device configured to deliver therapy for a respective organ type (e.g., a first generator configured to deliver neuromodulation therapy to a renal region and a second generator configured to deliver neuromodulation therapy to a hepatic region). In some such examples, processing circuitry 170 is configured to select one of the medical devices (or generators) for delivering therapy, instead of, or in addition to, selecting the therapy program. Likewise, processing circuitry 170 may be configured to select one of multiple therapy delivery elements 26 based on the organ type. Accordingly, processing circuitry 170 may select one or more of an appropriate therapy program, an appropriate therapy device, or an appropriate therapy delivery element to deliver therapy to the anatomical region, based on the organ type associated with the anatomical region.
[0075] Examples of techniques for determining organ types based on imaging using system 10 are described with reference to FIGS. 3 to 6.
[0076] FIG. 3 is a schematic diagram illustrating a scheme for determining an organ type based on at least one image indicative of a take-off angle of a blood vessels. For example,A0013531W001processing circuitry 170 may receive an image signal (e.g., from imaging system 44) indicative of a first image of an anatomical region obtained at a first comparative angle, a second image of the anatomical region obtained at a second comparative angle, and a third image of the anatomical region obtained at a third comparative angle. Based on the first image, processing circuitry 170 may determine a trunk, and a first blood vessel and a second blood vessel having an apparent lateral take-off relative to the trunk (e.g., aorta). Based on the second and third image showing views at different comparative angles relative to the first image, processing circuitry 170 may confirm the lateral take-off (and a somewhat slightly dorsal angle) determined from the first image. For example, in the second view, the projected length of the vessels identified as having a lateral take-off may be shorter than in the first view, and in the third view, the first blood vessel and the second blood vessel may disappear against the trunk or have an even shorter projected length. Accordingly, processing circuitry 170 may determine the first blood vessel and the second blood vessel as having a lateral takeoff, and determine the first blood vessel and the second blood vessel as being renal vessels.
[0077] Based on the third image, processing circuitry 170 may determine a third blood vessel having an apparent ventral take-off relative to the trunk (e.g., celiac trunk). Based on the first and second image showing views at different comparative angles relative to the third image, processing circuitry 170 may confirm the ventral take-off determined from the third image. For example, in the second image, the projected length of the third blood vessels identified as having a ventral take-off may be shorter than in the third image, and in the first view, the third blood vessel may disappear against the trunk or have an even shorter projected length. Accordingly, processing circuitry 170 may determine the third blood vessel as having a ventral take-off, and determine the third blood vessel as being a hepatic vessel.
[0078] Thus, using two or more images of the anatomical region at different projection angles may allow determination of whether a particular vessel has a lateral or ventral take-off, therefore respectively identifying the vessel as renal type or celiac (hepatic).
[0079] FIG. 4 is a schematic diagram illustrating a scheme for determining an organ type based on at least one image indicative of a presence or absence of an organ outline.Vasculature associated with certain organs may exhibit a discernible edge or shadow in response to flow of a contrast agent. For example, when taking fluoroscopic images of the renal arteries, the contrast agent fills into the kidneys and creates a perceptible shadow outline of the organ. In contrast, other organs may not exhibit an outline in response to receiving contrast agent. For example, when taking fluoroscopic images of the hepatic artery, the contrast agent gets dispersed into the multiple branching arteries (left / right hepatic, splenic,A0013531W001and gastroduodenal) rather than into a single organ. Accordingly, the fluoroscopic image is diffuse and does not show a perceptible outline of the liver. Accordingly, processing circuitry 170 may determine a presence or absence of a kidney in an anatomical region in response to a presence or absence of an edge, shadow, or outline in that anatomical region. In some examples, the scheme of FIG. 4 is useful in determining whether an image is indicative of either renal or hepatic organ type, without regard to other organ types (e.g., a binary decision).
[0080] FIG. 5 is a schematic diagram illustrating a scheme for using a machine learning model to determine an organ type based on at least one image. A machine learning model may be trained using an image database including a plurality of images, e.g., from a patient cohort. The images in the database may be labeled (e.g., as hepatic, renal, etc.) or unlabeled. Based on whether the images are labeled or unlabeled, an appropriate machine learning model may be selected for training. The machine learning model may be trained by supervised or unsupervised learning.
[0081] In some examples, the machine learning model includes pre-processing, such as feature extraction, followed by classification, for example, through a multi-layer network of weighted nodes. The weights of the nodes may be adjusted in course of training. The machine learning model may be trained to generate a binary output of organ type (e.g., renal type or hepatic type), or an output indicative of more than two organ types. In some examples, the machine learning model (or another model or technique) may be used to select, set, or determine a therapy program (or at least one therapy program parameter) based on the organ type. In some examples, the machine learning model is configured to generate an output indicative of the therapy program (or at least one therapy program parameter), in addition to, or instead of, the output indicative of the organ type.
[0082] The trained machine learning model may be used to categorize input images having an unknown organ type. For example, the input may include one or more images from an anatomical region of the patient. The trained machine learning model may process the one or more images and generate an output indicative of the organ type and / or the therapy program for that anatomical region.
[0083] FIG. 6 is a flow diagram illustrating an example technique for neuromodulation. The example technique of FIG. 6 is described with reference to system 10 of FIG. 1 and processing circuitry 170 of computing device 16 of FIG. 2. However, the example technique may be implemented by any suitable computing device, controller, catheter, or system alone or in combination with processing circuitry 170.A0013531W001
[0084] The technique includes receiving, by processing circuitry 170, an image signal indicative of at least one image of an anatomical region in which catheter 12 is positioned (200). The at least one image may include any suitable image. In some examples, the at least one image includes at least one fluoroscopic image. In some examples, the at least one image includes or consists of a plurality of fluoroscopic images.
[0085] The technique may further include determining, by processing circuitry 170, based on the image signal, an organ type associated with the anatomical region (202). In some examples, the organ type is selected from a group consisting of the renal type or the hepatic type. The determining the organ type associated with the anatomical region (202) may include, by processing circuitry 170, determining a blood vessel type associated with the anatomical region. For example, the blood vessel type may include a renal artery or a hepatic artery. In some examples, determining the blood vessel type includes, by processing circuitry 170, determining a take-off geometry of at least one blood vessel from another blood vessel or a trunk. For example, the image signal may be indicative of at least two images differing in an image projection angle. The determining the take-off geometry of the at least one blood vessel from the other blood vessel or the trunk may include, by processing circuitry 170, comparing the at least two images. For example, the determining the blood vessel type may include, by processing circuitry 170, determining the blood vessel type as renal type in response to determining that the at least one blood vessel has a lateral or slightly dorsal takeoff from the aorta. Vice versa, the determining the blood vessel type may include determining the blood vessel type as hepatic type in response to determining that the at least one blood vessel has a ventral take-off from the aorta.
[0086] In some examples, the at least one image includes at least one contrast image. For example, a contrast agent may be administered to the patient (e.g., in a blood vessel), and the at least one image may include a representation of the contrast agent in the anatomical region. In some such examples, determining the organ type associated with the anatomical region includes, by processing circuitry 170, determining a presence of a shadow outline of an organ in the at least one contrast image. For example, determining the organ type associated with the anatomical region (202) may include, by processing circuitry 170, determining the organ type as renal type in response to determining that shadow outline is present. Vice versa, determining the organ type associated with the anatomical region (202) may include, by processing circuitry 170, determining the organ type as hepatic type in response to determining that the shadow outline is absent.A0013531W001
[0087] In some examples, after the determining the organ type (202), the technique may include generating an output or alert indicative of the organ type, and receiving an input from a clinician confirming the determination of the organ type. For example, the clinician input may indicate that the determined organ type is correct, and the technique may proceed with subsequent steps. If the clinician input indicates that the determined organ type is incorrect or indeterminate, one or both of receiving the image signal (200) or determining the organ type (202) may be repeated, for example, based on the same images, similar images, or additional images as those used in an initial determination.
[0088] The technique may further include selecting, by processing circuitry 170, based on the organ type, a therapy program (204). The technique may further include performing, by processing circuitry 170, at least one action based on the therapy program (206). Performing the at least one action (206) may include generating, by processing circuitry 170, an output, an alert, or an indicator signal indicative of one or both of the organ type or the therapy program. The output may include a visual representation (e.g., a chart, an image, a plot, an overlay, an alphanumerical output, or any other representation) of the organ type, or another representation. For example, the output may include a tactile representation (a first vibration or tactile pattern indicative of a first organ type and a second vibration or tactile pattern indicative of a second organ type). The output may include an audible representation (a first audio output indicative of a first organ type and a second audio output indicative of a second organ type). In some examples, the audible representation may include a word or a phrase, for example, “renal region detected” or “hepatic region detected.”
[0089] The technique may further include delivering (e.g., by medical device 18) therapy (e.g„ neuromodulation therapy) based on the therapy program (208). For example, medical device 18 may cause at least one therapy delivery element 26 to deliver therapy based on the therapy program. For example, the technique may further include, by processing circuitry 170, selecting a renal neuromodulation program as the therapy program in response to determining that the organ type is a renal type. Vice versa, the technique may further include, by processing circuitry 170, selecting a hepatic neuromodulation program as the therapy program in response to determining that the organ type is a hepatic type. Accordingly, delivering the therapy based on the therapy program (208) may be tailored to the organ type associated with the anatomical region. In some examples, the delivering the therapy based on therapy program (208) includes, by catheter 12 introduced in a blood vessel, neuromodulation therapy based on the therapy program to the patient. For example, the technique may further include generating, by processing circuitry 170, based on the therapy program, a therapyA0013531W001signal configured to cause therapy delivery element 26 of neuromodulation catheter 12 to deliver the neuromodulation therapy to the patient.
[0090] FIG. 7 illustrates an example technique for accessing a renal artery and modulating renal nerves with a neuromodulation catheter. While FIG. 7 illustrates the use of catheter 12 for renal neuromodulation, catheter 12 may be used for other therapies and treatments within another blood vessel or other hollow anatomical body within the human body. Catheter 12 is configured to deliver energy (e.g., RF energy, ultrasound energy, electrical stimulation energy, or the like) to one or more target tissue sites within a renal vessel. Catheter 12 provides access to the renal plexus (RP) through an intravascular path (P), such as a percutaneous access site in the femoral (illustrated), brachial, radial, or axillary artery to the target tissue sites within a respective renal artery (RA). By manipulating proximal portion 22B or elongate body 22 from outside the intravascular path (P), a clinician may advance distal portion 22A of elongate body 22 through the sometimes-tortuous intravascular path (P) and remotely manipulate distal portion 22A (FIG. 1) of elongate body 22. Distal portion 22A may be remotely manipulated by the clinician using handle 20.
[0091] In the example illustrated in FIG. 7, distal portion 22A is delivered intravascularly to the treatment site using an inner member 123 in an over-the-wire (OTW) technique. Inner member 123 may be internal to catheter 12 (e.g., a guide wire, inner catheter, or the like) or external to catheter 12 (e.g., an outer sheath or the like). In some examples, inner member 123 is a navigation wire. Catheter 12 may define a passageway for receiving inner member 23 for delivery of catheter 12 using either an OTW or an RX technique. At the treatment site, inner member 123 can be at least partially withdrawn or removed relative to catheter 12 and distal portion 22A can transform into an expanded configuration (for example, a helical configuration, a spiral configuration, or the like) for delivering ultrasound energy. In other examples, elongate body 22 is self-steerable such that therapy may be delivered via the target tissue site without the aid of inner member 123.
[0092] In some examples, catheters described herein may be used to perform renal modulation. Renal modulation is the partial or complete incapacitation or other effective disruption of nerves of the kidneys (e.g., nerves terminating in the kidneys or in structures closely associated with the kidneys). In particular, renal neuromodulation can include inhibiting, reducing, or blocking neural communication along neural fibers (e.g., efferent or afferent neural fibers) of the kidneys. Such incapacitation can be long-term (e.g., permanent or for a period of months, years, or decades) or short-term (e.g., for periods of minutes, hours, days, or weeks). Renal neuromodulation is expected to contribute to the systemic reduction ofA0013531W001sympathetic tone or drive or benefit at least some specific organs or other bodily structures innervated by sympathetic nerves. Accordingly, renal neuromodulation is expected to be useful in treating clinical conditions associated with central sympathetic overstimulation. For example, renal neuromodulation is expected to efficaciously treat hypertension, heart failure, acute myocardial infarction, metabolic syndrome, insulin resistance, diabetes, left ventricular hypertrophy, chronic and end state renal disease, inappropriate fluid retention in heart failure, cardio-renal syndrome, polycystic kidney disease, polycystic ovary syndrome, osteoporosis, erectile dysfunction, and sudden death, among other conditions.
[0093] Renal neuromodulation can be electrically induced or induced in another suitable manner through the delivery of energy (RF energy, ultrasound energy, microwave energy, or the like). The target tissue site can be within or otherwise proximate to a renal lumen (e.g., a renal artery, a ureter, a renal pelvis, a major renal calyx, a minor renal calyx, or another suitable structure), and the target tissue site can include tissue at least proximate to a wall of the renal lumen. For example, with regard to a renal artery, a treatment procedure can include modulating nerves in the renal plexus, which lay intimately within or adjacent to the adventitia of the renal artery. The following discussion provides further details regarding patient anatomy and physiology as it may relate to renal denervation therapy. This section is intended to supplement and expand upon the previous discussion regarding the relevant anatomy and physiology, and to provide additional context regarding the disclosed technology and the therapeutic benefits associated with renal denervation. For example, several properties of the renal vasculature may inform the design of the target tissue devices and associated methods for achieving renal neuromodulation via intravascular access and may impose specific design requirements for such devices. Specific design requirements may include accessing the renal artery, positioning distal portion 22A within the renal artery, delivering the therapy to targeted tissue, or effectively modulating the renal nerves with the therapy delivery device.
[0094] As noted previously, the sympathetic nervous system (SNS) is a branch of the autonomic nervous system along with the enteric nervous system and parasympathetic nervous system. It is always active at a basal level (called sympathetic tone) and becomes more active during times of stress. Like other parts of the nervous system, the sympathetic nervous system operated through a series of interconnected neurons. Sympathetic neurons are frequently considered part of the peripheral nervous system (PNS), although many lie within the central nervous system (CNS). Sympathetic neurons of the spinal cord (which is part of the CNS) communicate with peripheral sympathetic neurons via a series of sympatheticA0013531W001ganglia. Within the ganglia, spinal cord sympathetic neurons are therefore called presynaptic (or preganglionic) neurons, while peripheral sympathetic neurons are called postsynaptic (or postganglionic neurons).
[0095] At synapses within the sympathetic ganglia, preganglionic sympathetic neurons release acetylcholine, a chemical messenger that binds and activates nicotinic acetylcholine receptors on postganglionic neurons. In response to this stimulus, postganglionic neurons principally release noradrenaline (norepinephrine). Prolonged activation may elicit the release of adrenaline from the adrenal medulla.
[0096] Once released, norepinephrine and epinephrine bind adrenergic receptors on peripheral tissues. Binding to adrenergic receptors causes a neuronal and hormonal response. The physiologic manifestations include pupil dilation, increased heart rate, occasional vomiting, and increased blood pressure. Increased sweating is also seen due to binding of cholinergic receptors of the sweat glands.
[0097] The sympathetic nervous system is responsible for up- and down-regulating many homeostatic mechanisms in living organisms. Fibers from the SNS innervate tissues in almost every organ system, providing at least some regulatory function to physiological features as diverse as pupil diameter, gut motility, and urinary output. This response is also known as sympatho-adrenal response of the body, as the preganglionic sympathetic fibers that end in the adrenal medulla (but also all other sympathetic fibers) secrete acetylcholine, which activates the secretion of adrenaline (epinephrine) and to a lesser extent noradrenaline (norepinephrine). Therefore, this response that acts primarily on the cardiovascular system is mediated directly via impulses transmitted through the sympathetic nervous system and indirectly via catecholamines secreted from the adrenal medulla.
[0098] FIG. 8 is a conceptual illustration of an example sympathetic nervous system (SNS) illustrating how the brain communicates with the body via the SNS. As shown in FIG.8, the SNS provides a network of nerves that allows the brain to communicate with the body. Sympathetic nerves originate inside the vertebral column, e.g., toward the middle of the spinal cord in the intermediolateral cell column (or lateral horn), beginning at the first thoracic segment of the spinal cord and are thought to extend to the second or third lumbar segments. Because SNS cells begin in the thoracic and lumbar regions of the spinal cord, the SNS is said to have a thoracolumbar outflow. Axons of sympathetic nerves leave the spinal cord through the anterior rootlet / root. The axons pass near the spinal (sensory) ganglion, where the axons enter the anterior rami of the spinal nerves. However, unlike somatic innervation, the axons separate out through white rami connectors which connect to either the paravertebral (whichA0013531W001lie near the vertebral column) or prevertebral (which lie near the aortic bifurcation) ganglia extending alongside the spinal column.
[0099] To reach the target organs and glands, the axons should travel long distances in the body, and, to accomplish this, many axons relay their message to a second cell through synaptic transmission. The ends of the axons link across a space, the synapse, to the dendrites of the second cell. The first cell (the presynaptic cell) sends a neurotransmitter across the synaptic cleft where it activates the second cell (the postsynaptic cell). The message is then carried to the final destination.
[0100] In the SNS and other component of the peripheral nervous system, these synapses are made at sites called ganglia, discussed above. The cell that sends its fiber to the ganglion is called a preganglionic cell, while the cell whose fiber leaves the ganglion is called a postganglionic cell. As mentioned previously, the preganglionic cell of the SNS is located between the first thoracic (Tl) segment and third lumbar (L3) segments of the spinal cord. Postganglionic cells have their cell bodies in the ganglia and send their axons to target organs or glands.
[0101] The ganglia include not just the sympathetic trunks but also the cervical ganglia (superior, middle, and inferior), which send sympathetic nerve fibers to the head and thorax organs, and the celiac and mesenteric ganglia, which send sympathetic fibers to the gut.
[0102] FIG. 9 is an enlarged anatomic view of nerves innervating a left kidney to form the renal plexus surrounding the left renal artery. As FIG. 9 shows, the kidney is innervated by the renal plexus (RP), which is intimately associated with the renal artery. The renal plexus (RP) is an autonomic plexus that surrounds the renal artery and is embedded within the adventitia of the renal artery. The renal plexus (RP) extends along the renal artery and is embedded within the adventitia of the renal artery. Fibers contributing to the renal plexus (RP) arise from the celiac ganglion, the superior mesenteric ganglion, the aorticorenal ganglion and the aortic plexus. The renal plexus (RP), also referred to as the renal nerve, is predominantly comprised of sympathetic components. There is no (or at least very minimal) parasympathetic innervation of the kidney.
[0103] Preganglionic neuronal cell bodies are located in the intermediolateral cell column of the spinal cord. Preganglionic axons pass through the paravertebral ganglia to become the lesser splanchnic nerve, the least splanchnic nerve, the first lumbar splanchnic nerve, the second lumbar splanchnic nerve, and travel to the celiac ganglion, the superior mesenteric ganglion, and the aorticorenal ganglion. Postganglionic neuronal cell bodies exit the celiacA0013531W001ganglion, the superior mesenteric ganglion, and the aorticorenal ganglion to the renal plexus (RP) and are distributed to the renal vasculature.
[0104] Messages travel through the SNS in a bi-directional flow. Efferent messages may trigger changes in different parts of the body simultaneously. For example, the sympathetic nervous system may accelerate heart rate, widen bronchial passages, decrease motility (movement) of the large intestine, constrict blood vessels, increase peristalsis in the esophagus, cause pupil dilation, piloerection (goose bumps) and perspiration (sweating), or raise blood pressure. Afferent messages carry signals from various organs and sensory receptors in the body to other organs and, particularly, the brain.
[0105] Hypertension, heart failure, and chronic kidney disease are a few of the many disease states that result from chronic activation of the SNS, especially the renal sympathetic nervous system. Chronic activation of the SNS is a maladaptive response that drives the progression of theses disease states. Pharmaceutical management of the renin-angiotensin-aldosterone system (RAAS) has been a longstanding, but somewhat ineffective, approach for reducing over-activity of the SNS.
[0106] As mentioned above, the renal sympathetic nervous system has been identified as a major contributor to the complex pathophysiology of hypertension, states of volume overload (such as heart failure) and progressive renal disease, both experimentally and in humans. Studies employing radiotracer dilution methodology to measure overflow of norepinephrine from the kidneys to plasma revealed increased renal norepinephrine (NE) spillover rates in patients with essential hypertension, particularly so in young hypertensive subjects, which in concert with increased NE spillover from the heart, is consistent with the hemodynamic profile typically seen in early hypertension and characterized by an increased heart rate, cardiac output, and renovascular resistance. It is now known that essential hypertension is commonly neurogenic, often accompanied by pronounced sympathetic nervous system overactivity.
[0107] Activation of cardiorenal sympathetic nerve activity is even more pronounced in heart failure, as demonstrated by an exaggerated increase of NE overflow from the heart and the kidneys to plasma in this patient group. In line with this notion is the recent demonstration of a strong negative predictive value of renal sympathetic activation on allcause mortality and heart transplantation in patients with congestive heart failure, which is independent of overall sympathetic activity, glomerular filtration late, and left ventricular ejection fraction. These findings support the notion that treatment regimens that are designedA0013531W001to reduce renal sympathetic stimulation have the potential to improve survival in patients with heart failure.
[0108] Both chronic and end state renal disease in some patients are characterized by heightened sympathetic nervous activation. In patients with end state renal disease, plasma levels of norepinephrine above the media have been demonstrated to be predictive for both all-cause death and death from cardiovascular disease. This can also be true for patients suffering from diabetic or contrast nephropathy. There is compelling evidence suggesting that sensory afferent signals originating from the diseased kidneys are major contributors to initiating and sustaining elevated central sympathetic outflow in this patient group; this facilitates the occurrence of the well-known adverse consequences of chronic sympathetic over activity, such as hypertension, left ventricular hypertrophy, ventricular arrhythmias, sudden cardiac death, insulin resistance, diabetes, and metabolic syndrome.
[0109] Sympathetic nerves to the kidneys terminate in the blood vessels, the juxtaglomerular apparatus, and the renal tubules. Stimulation of the renal sympathetic nerves cause increased renin release, increased sodium (Na+) reabsorption, and a reduction of renal blood flow. These components of the neural regulation of renal function are considerably stimulated in disease states characterized by heightened sympathetic tone and clearly contribute to the rise in blood pressure in hypertensive patients. The reduction of renal blood flow and glomerular filtration rate as a result of renal sympathetic efferent stimulation may be a cornerstone of the loss of renal function in cardio-renal syndrome, which is renal dysfunction as a progressive complication of chronic heart failure, with a clinical course that typically fluctuates with the patient’s clinical status and treatment. Pharmacologic strategies to thwart the consequences of renal efferent sympathetic stimulation include centrally acting sympatholytic drugs, beta blockers (intended to reduce renin release), angiotensin converting enzyme inhibitors and receptor blockers (intended to block the action of angiotensin II and aldosterone activation consequent to renin release), and diuretics (intended to counter the renal sympathetic mediated sodium and water retention). However, the current pharmacologic strategies can have significant limitations including limited efficacy, compliance issues, side effects, and others.
[0110] The kidneys communicate with integral structures in the central nervous system via renal sensory afferent nerves. Several forms of “renal injury” may induce activation of sensory afferent signals. For example, renal ischemia, reduction in stroke volume or renal blood flow, or an abundance of adenosine enzyme may trigger activation of afferent neural communication.A0013531W001[OHl] FIG. 10 is an anatomic view of a human body depicting neural efferent and afferent communication between the brain and kidneys. FIG. 11 is a conceptual view of a human body depicting neural efferent and afferent communication between the brain and kidneys. As shown in FIGS. 10 and 11, the afferent communication might be from kidney to the brain or might be from one kidney to the other kidney (via the central nervous system). These afferent signals are centrally integrated and may result in increased sympathetic outflow. This sympathetic drive is directed towards the kidneys, thereby activating the RAAS and inducing increased renin secretion, sodium retention, volume retention, and vasoconstriction. Central sympathetic over activity also impacts other organs and bodily structures innervated by sympathetic nerves such as the heart and the peripheral vasculature, resulting in the described adverse effects of sympathetic activation, several aspects of which also contribute to the rise in blood pressure.
[0112] The physiology therefore suggests that (i) modulation of tissue with efferent sympathetic nerves will reduce inappropriate renin release, salt retention, and reduction of renal blood flow, and that (ii) modulation of tissue with afferent sensory nerves will reduce the systemic contribution to hypertension and other disease states associated with increased central sympathetic tone through its direct effect on the posterior hypothalamus as well as the contralateral kidney. In addition to the central hypotensive effects of afferent renal denervation, a desirable reduction of central sympathetic outflow to various other sympathetically innervated organs such as the heart and the vasculature is anticipated.
[0113] As provided above, renal denervation is likely to be valuable in the treatment of several clinical conditions characterized by increased overall and particularly renal sympathetic activity such as hypertension, metabolic syndrome, insulin resistance, diabetes, left ventricular hypertrophy, chronic end state renal disease, inappropriate fluid retention in heart failure, cardio-renal syndrome and sudden death. Since the reduction of afferent neural signals contributing to the systemic reduction of sympathetic tone / drive, renal denervation might also be useful in treating other conditions associated with systemic sympathetic hyperactivity. Accordingly, renal denervation may also benefit other organs and bodily structures innervated by sympathetic nerves, including those identified in FIG. 11. For example, as previously discussed, a reduction in central sympathetic drive may reduce the insulin resistance that afflicts people with metabolic syndrome and Type II diabetics.Additionally, patients with osteoporosis may also be sympathetically activated and might also benefit from the down regulation of sympathetic drive that accompanies renal denervation.A0013531W001
[0114] In accordance with the present technology neuromodulation of a left or right renal plexus (RP), which is intimately associated with a left or right renal artery, may be achieved through intravascular access. FIG. 12 is an anatomic view of the arterial vasculature of a human. As FIG. 12 shows, blood moved by contractions of the heart is conveyed from the left ventricle of the heart by the aorta. The aorta descends through the thorax and branches into the left and right renal arteries. Below the renal arteries, the aorta bifurcates at the left and right iliac arteries. The left and right iliac arteries descend, respectively, through the left and right legs and join the left and right femoral arteries.
[0115] FIG. 13 is an anatomic view of the venous vasculature of a human. As FIG. 13 shows, the blood collects in veins and returns to the heart, through the femoral veins into the iliac veins and into the inferior vena cava. The inferior vena cava branches into the left and right renal veins. Above the renal veins, the inferior vena cava ascends to convey blood into the right atrium of the heart. From the right atrium, the blood is pumped through the right ventricle into the lungs, where it is oxygenated. From the lungs, the oxygenated blood is conveyed into the left atrium. From the left atrium, the oxygenated blood is conveyed by the left ventricle back to the aorta.
[0116] The femoral artery may be accessed and cannulated at the base on the femoral triangle just inferior to the midpoint of the inguinal ligament. A catheter may be inserted percutaneously into the femoral artery through this access site, passed through the iliac artery and aorta, and placed into either the left or right renal artery. This comprises an intravascular path that offers minimally invasive access to a respective renal artery or other renal blood vessels.
[0117] The wrist, upper arm, and shoulder region provide other locations for introduction of catheters into the arterial system. For example, catheterization of either the radial, brachial, or axillary artery may be utilized in select cases. Catheters (e.g., catheter 12) introduced via these access points may be passed through the subclavian artery on the left side (or via the subclavian and brachiocephalic arteries on the right side), through the aortic arch, down the descending aorta and into the renal arteries using standard angiographic techniques. Other access sites can also be used to access the arterial system.
[0118] Since neuromodulation of a left or right renal plexus (RP) may be achieved in accordance with the present technology through intravascular access, properties and characteristics of the renal vasculature may impose constraints upon or inform the design of apparatus, systems, and methods for achieving such renal neuromodulation. Some of these properties and characteristics may vary across the patient population or within a specificA0013531W001patient across time, as well as in response to disease states, such as hypertension, chronic kidney disease, vascular disease, end-stage renal disease, insulin resistance, diabetes, metabolic syndrome, and the like. These properties and characteristics, as explained herein, may have bearing on the efficacy of the procedure and the specific design of the intravascular device. Properties of interest may include, for example, material / mechanical, spatial, fluid dynamic / hemodynamic or thermodynamic properties.
[0119] As discussed previously, a catheter may be advanced percutaneously into either the left or right renal artery via a minimally invasive intravascular path. However, minimally invasive renal arterial access may be challenging, for example, because as compared to some other arteries that are routinely accessed using catheters, the renal arteries are often extremely tortuous, may be of relatively small diameter, or may be of relatively short length.Furthermore, renal arterial atherosclerosis is common in many patients, particularly those with cardiovascular disease. Renal arterial anatomy also may vary significantly from patient to patient, which further complicates minimally invasive access. Significant inter-patient variation may be seen, for example, in relative tortuosity, diameter, length, or atherosclerotic plaque burden, as well as in the take-off angle at which a renal artery branches from the aorta. Further, some patients include multiple left renal arteries or right renal arteries. Apparatus, systems, and methods for achieving renal neuromodulation via intravascular access should account for these and other aspects of renal arterial anatomy and its variation across the patient population when minimally invasively accessing a renal artery.
[0120] In addition to complicating renal arterial access, specifics of the renal anatomy also complicate establishment of stable contact between neuromodulatory apparatus and a luminal surface or wall of a renal artery. For example, navigation can be impeded by the tight space within a renal artery, as well as tortuosity of the artery. Furthermore, establishing consistent contact is complicated by patient movement, respiration, or the cardiac cycle because these factors may cause significant movement of the renal artery relative to the aorta, and the cardiac cycle may transiently distend the renal artery (i.e., cause the wall of the artery to pulse).
[0121] The neuromodulation system may also be configured to allow for adjustable positioning and repositioning of distal portion 22A (FIG. 1) within the renal artery since location of treatment may also impact clinical efficacy. Additionally, variable positioning and repositioning of the neuromodulatory apparatus may prove to be useful in circumstances where the renal artery is particularly tortuous or where there are proximal branch vessels off the renal artery main vessel, making treatment in certain locations challenging.A0013531W001
[0122] As noted above, an apparatus positioned within a renal artery may be configured so that distal portion 22A of catheter 12 may intimately contact the vessel wall or extend at least partially through the vessel wall. Renal artery vessel diameter, DRA, typically is in a range of about 2-10 mm, with most of the patient population having a DRA of about 4 mm to about 8 mm and an average of about 6 mm. Renal artery vessel length, LRA, between its ostium at the aorta / renal artery juncture and its distal branchings, generally is in a range of about 5-70 mm, and a significant portion of the patient population is in a range of about 20-50 mm. Since the target renal plexus is embedded within the adventitia of the renal artery, the composite Intima-Media Thickness, IMT, (i.e., the radial outward distance from the artery's luminal surface to the adventitia containing target neural structures) also is notable and generally is in a range of about 0.5-2.5 mm, with an average of about 1.5 mm. Although a certain depth of treatment is important to reach the target neural fibers, the treatment should not be too deep (e.g., > 10 mm from inner wall of the artery) to avoid non-target tissue and anatomical structures such as anatomical structures of the digestive system of psoas muscle.
[0123] An additional property of the renal artery that may be of interest is the degree of renal motion relative to the aorta induced by respiration or blood flow pulsatility. A patient’s kidney, which is located at the distal end of the renal artery, may move as much as 10 centimeters cranially with respiratory excursion. This may impart significant motion to the renal artery connecting the aorta and the kidney, thereby requiring from the neuromodulatory apparatus a unique balance of stiffness and flexibility to maintain contact between the energy delivery element and the vessel wall during cycles of respiration. Furthermore, the take-off angle between the renal artery and aorta may vary significantly between patients, and also may vary dynamically within a patient, e.g., due to kidney motion. The take-off angle generally may be in a range of about 30°-135°.
[0124] In general, the devices, systems, and techniques described herein may be used in conjunction with neuromodulation performed from within any suitable anatomical lumen that has nerves adjacent to the anatomical lumen. Example anatomical lumens include the celiac trunk and its branches (including the common hepatic artery and its branches, the gastroduodenal artery and its branches, the right gastric artery and its branches, and the proper hepatic artery and its branches, the left gastric artery and its branches, and the splenic artery and its branches), the superior mesenteric artery and its branches, the gonadal artery and its branches, the inferior mesenteric artery and its branches, and the like. Further, although the disclosure primarily describes neuromodulation from within one or more arteries, the devices, systems, and techniques of the disclosure also may be applied to neuromodulation fromA0013531W001within one or more veins, such as a renal vein and its branches, a hepatic vein and its branches, an intercostal vein and its branches, or the like.
[0125] In some implementations, the devices, systems, and techniques described herein may be used to perform neuromodulation from within two or more anatomical lumens, e.g., in the renal arteries and the common hepatic artery, or any other combination of two or more anatomical lumens, either simultaneously or sequentially. In addition, the systems, devices, and methods described herein may be useful in conjunction with neuromodulation within a body lumen other than a vessel, for extravascular neuromodulation and / or for use in conjunction with therapies other than neuromodulation.
[0126] The following enumerated clauses describe examples according to the present disclosure.
[0127] Clause 1: A system including: processing circuitry configured to: receive an image signal indicative of at least one image of an anatomical region in which a catheter is positioned; determine, based on the image signal, an organ type associated with the anatomical region; select, based on the organ type, a therapy program; and perform at least one action based on the therapy program.
[0128] Clause 2: The system of clause 1, where the therapy program is configured to, when delivered via a therapy delivery element, cause neuromodulation of nerves associated with the organ type at the anatomical region.
[0129] Clause 3: The system of clause 2, where the therapy program is configured to, when delivered via the therapy delivery element, cause denervation of the nerves associated with the organ type at the anatomical region.
[0130] Clause 4: The system of any of clauses 1 to 3, where to perform the at least one action, the processing circuitry is configured to generate an output, an alert, or an indicator signal indicative of one or both of the organ type or the therapy program.
[0131] Clause 5: The system of any of clauses 1 to 4, where the at least one image includes at least one of a fluoroscopic image, a computed tomography (CT) image, or a magnetic resonance imaging (MRI) image.
[0132] Clause 6: The system of any of clauses 1 to 5, where the processing circuitry is further configured to: select a renal neuromodulation program as the therapy program in response to determining that the organ type is a renal type; and select a hepatic neuromodulation program as the therapy program in response to determining that the organ type is a hepatic type.A0013531W001
[0133] Clause 7: The system of clause 6, where the organ type is selected from a group consisting of the renal type or the hepatic type.
[0134] Clause 8: The system of any of clauses 1 to 7, where to determine the organ type associated with the anatomical region, the processing circuitry is further configured to determine a blood vessel type associated with the anatomical region.
[0135] Clause 9: The system of clause 8, where the blood vessel type includes a renal artery or a hepatic artery.
[0136] Clause 10: The system of clauses 8 or 9, where to determine the blood vessel type, the processing circuitry is configured to determine a take-off geometry of at least one blood vessel from another blood vessel or a trunk.
[0137] Clause 11 : The system of clause 10, where the image signal is indicative of at least two images differing in an image projection angle, and where to determine the take-off geometry of the at least one blood vessel from the other blood vessel or the trunk, the processing circuitry is configured to compare the at least two images.
[0138] Clause 12: The system of clauses 10 or 11, where the processing circuitry is configured to determine the blood vessel type as renal type in response to determining that the at least one blood vessel has a lateral or slightly dorsal take-off from the aorta; and where the processing circuitry is configured to determine the blood vessel type as hepatic type in response to determining that the at least one blood vessel has a ventral take-off from the aorta.
[0139] Clause 13: The system of any of clauses 1 to 12, where the at least one image includes at least one contrast image, and where, to determine the organ type associated with the anatomical region, the processing circuitry is further configured to determine a presence of a shadow outline of an organ in the at least one contrast image.
[0140] Clause 14: The system of clause 13, where the processing circuitry is configured to determine the organ type as renal type in response to determining that shadow outline is present; and where the processing circuitry is configured to determine the organ type as hepatic type in response to determining that the shadow outline is absent.
[0141] Clause 15: The system of any of clauses 1 to 14, where to perform the at least one action, the processing circuitry is configured to generate an output, an alert, or an indicator signal indicative of one or both of the organ type or the therapy program, the system further including a neuromodulation generator configured to: receive the indicator signal from the processing circuitry; and based on the indicator signal, generate a therapy signal for delivery to a neuromodulation catheter configured to deliver neuromodulation therapy.A0013531W001
[0142] Clause 16: The system of clause 15, where the neuromodulation generator includes the processing circuitry.
[0143] Clause 17: The system of clauses 15 or 16, further including a neuromodulation catheter configured to be introduced in a blood vessel and deliver the neuromodulation therapy to the patient.
[0144] Clause 18: The system of clause 17, where the neuromodulation catheter includes: an elongate body configured to transform from a relatively low profile configuration to an expanded configuration; and a therapy delivery element disposed on the elongate body and configured to deliver the neuromodulation therapy based on the therapy signal.
[0145] Clause 19: A method including: receiving, by processing circuitry, an image signal indicative of at least one image of an anatomical region in which a catheter is positioned; determining, by the processing circuitry, based on the image signal, an organ type associated with the anatomical region; selecting, by the processing circuitry, based on the organ type, a therapy program; and performing, by the processing circuitry, at least one action based on the therapy program.
[0146] Clause 20: The method of clause 19, further including delivering neuromodulation therapy based on the therapy program.
[0147] Clause 21 : The method of any of clauses 19 to 20, where performing the at least one action includes generating, by the processing circuitry, an output, an alert, or an indicator signal indicative of one or both of the organ type or the therapy program.
[0148] Clause 22: The method of any of clauses 19 to 21, where the at least one image includes at least one of a fluoroscopic image, a computed tomography (CT) image, or a magnetic resonance imaging (MRI) image.
[0149] Clause 23: The method of any of clauses 19 to 22, further including, by the processing circuitry: selecting a renal neuromodulation program as the therapy program in response to determining that the organ type is a renal type; and selecting a hepatic neuromodulation program as the therapy program in response to determining that the organ type is a hepatic type.
[0150] Clause 24: The method of clause 23, where the organ type is selected from a group consisting of the renal type or the hepatic type.
[0151] Clause 25: The method of any of clauses 19 to 24, where the determining the organ type associated with the anatomical region includes, by the processing circuitry, determining a blood vessel type associated with the anatomical region.A0013531W001
[0152] Clause 26: The method of clause 25, where the blood vessel type includes a renal artery or a hepatic artery.
[0153] Clause 27: The method of clauses 25 or 26, where the determining the blood vessel type includes, by the processing circuitry, determining a take-off geometry of at least one blood vessel from another blood vessel or a trunk.
[0154] Clause 28: The method of clause 27, where the image signal is indicative of at least two images differing in an image projection angle, and where the determining the takeoff geometry of the at least one blood vessel from the other blood vessel or the trunk includes, by the processing circuitry, comparing the at least two images.
[0155] Clause 29: The method of clauses 27 or 28, where the determining the blood vessel type includes, by the processing circuitry: determining the blood vessel type as renal type in response to determining that the at least one blood vessel has a lateral or slightly dorsal take-off from the aorta; and determining the blood vessel type as hepatic type in response to determining that the at least one blood vessel has a ventral take-off from the aorta.
[0156] Clause 30: The method of any of clauses 19 to 29, where the at least one image includes at least one contrast image, and where determining the organ type associated with the anatomical region includes, by the processing circuitry, determining a presence of a shadow outline of an organ in the at least one contrast image.
[0157] Clause 31 : The method of clause 30, where determining the organ type associated with the anatomical region includes, by the processing circuitry: determining the organ type as renal type in response to determining that shadow outline is present; and determining the organ type as hepatic type in response to determining that the shadow outline is absent.
[0158] Clause 32: The method of any of clauses 19 to 31, further including delivering, by a neuromodulation catheter introduced in a blood vessel, neuromodulation therapy based on the therapy program to the patient.
[0159] Clause 33: The method of clause 32, further including generating, by the processing circuitry, based on the therapy program, a therapy signal configured to cause a therapy delivery element of the neuromodulation catheter to deliver the neuromodulation therapy to the patient.
[0160] Clause 34: A system including means for performing the method of any of clauses 19 to 33.
[0161] Clause 35: A system including processing means for performing the method of any of clauses 19 to 33.A0013531W001
[0162] Clause 36: A non-transitory computer-readable storage medium including program instructions that, when executed by processing circuitry, are configured to cause the processing circuitry to perform the method of any of clauses 19 to 33.
[0163] Certain aspects of the present disclosure described in the context of particular examples may be combined or eliminated in other examples. Further, while advantages associated with certain examples have been described in the context of those examples, other examples may also exhibit such advantages, and not all examples need necessarily exhibit such advantages to fall within the scope of the present disclosure. Accordingly, the present disclosure and associated technology can encompass other examples not expressly shown or described herein.
[0164] Moreover, unless the word “or” is expressly limited to mean only a single term exclusive from the other items in reference to a list of two or more items, then the use of “or” in such a list is to be interpreted as including (a) any single item in list, (b) all of the items in the list, or (c) any combination of the items in the list. Additionally, the term “comprising” is used throughout to mean including at least the recited feature(s) such that any greater number of the same feature and / or additional types of other features are not precluded.
[0165] It should be understood that various aspects disclosed herein may be combined in different combinations than the combinations specifically presented in the description and accompanying drawings. It should also be understood that, depending on the example, certain acts or events of any of the processes or methods described herein may be performed in a different sequence, may be added, merged, or left out altogether (e.g., all described acts or events may not be necessary to carry out the techniques). In addition, while certain aspects of this disclosure are described as being performed by a single module, unit, or circuit for purposes of clarity, it should be understood that the techniques of this disclosure may be performed by a combination of units, modules, or circuitry associated with, for example, a medical device.
[0166] In one or more examples, the described techniques may be implemented in hardware, software, firmware, or any combination thereof. If implemented in software, the functions may be stored as one or more instructions or code on a computer-readable medium and executed by a hardware-based processing unit. Computer-readable media may include non-transitory computer-readable media, which corresponds to a tangible medium such as data storage media (e.g., RAM, ROM, EEPROM, flash memory, or any other medium that can be used to store desired program code in the form of instructions or data structures and that can be accessed by a computer).A0013531W001
[0167] Instructions may be executed by one or more processors that include processing circuitry, such as one or more digital signal processors (DSPs), general purpose microprocessors, application specific integrated circuits (ASICs), field programmable logic arrays (FPGAs), or other equivalent integrated or discrete logic circuitry. Accordingly, the term “processor” or “processing circuitry” as used herein may refer to any of the foregoing structure or any other physical structure suitable for implementation of the described techniques. Also, the techniques could be fully implemented in one or more circuits or logic elements.
[0168] The above detailed descriptions of examples of the technology are not intended to be exhaustive or to limit the technology to the precise form disclosed above. Although specific examples of the technology are described above for illustrative purposes, various equivalent modifications are possible within the scope of the technology, as those skilled in the relevant art will recognize. For example, while steps are presented in a given order, alternative examples may perform steps in a different order. The various examples described herein may also be combined to provide further examples. All references cited herein are incorporated by reference as if fully set forth herein.
[0169] From the foregoing, it will be appreciated that specific examples of the present disclosure have been described herein for purposes of illustration, but that various modifications may be made without deviating from the present disclosure.
[0170] Various examples have been described. These and other examples are within the scope of the following claims.
Claims
A0013531W001CLAIMS1. A system comprising:processing circuitry configured to:receive an image signal indicative of at least one image of an anatomical region in which a catheter is positioned;determine, based on the image signal, an organ type associated with the anatomical region;select, based on the organ type, a therapy program; andperform at least one action based on the therapy program.
2. The system of claim 1, wherein the therapy program is configured to, when delivered via a therapy delivery element, cause neuromodulation of nerves associated with the organ type at the anatomical region.
3. The system of claim 2, wherein the therapy program is configured to, when delivered via the therapy delivery element, cause denervation of the nerves associated with the organ type at the anatomical region.
4. The system of any one of claims 1 to 3, wherein to perform the at least one action, the processing circuitry is configured to generate an output, an alert, or an indicator signal indicative of one or both of the organ type or the therapy program.
5. The system of any one of claims 1 to 4, wherein the at least one image comprises at least one of a fluoroscopic image, a computed tomography (CT) image, or a magnetic resonance imaging (MRI) image.
6. The system of any one of claims 1 to 5, wherein the processing circuitry is further configured to:select a renal neuromodulation program as the therapy program in response to determining that the organ type is a renal type; andselect a hepatic neuromodulation program as the therapy program in response to determining that the organ type is a hepatic type.A0013531W0017. The system of any one of claims 1 to 6, wherein to determine the organ type associated with the anatomical region, the processing circuitry is further configured to determine a blood vessel type associated with the anatomical region.
8. The system of claim 7, wherein to determine the blood vessel type, the processing circuitry is configured to determine a take-off geometry of at least one blood vessel from another blood vessel or a trunk.
9. The system of claim 8, wherein the image signal is indicative of at least two images differing in an image projection angle, and wherein to determine the take-off geometry of the at least one blood vessel from the other blood vessel or the trunk, the processing circuitry is configured to compare the at least two images.
10. The system of claims 8 or 9, wherein the processing circuitry is configured to determine the blood vessel type as renal type in response to determining that the at least one blood vessel has a lateral or slightly dorsal take-off from the aorta; andwherein the processing circuitry is configured to determine the blood vessel type as hepatic type in response to determining that the at least one blood vessel has a ventral take-off from the aorta.
11. The system of any one of claims 1 to 10, wherein the at least one image comprises at least one contrast image, andwherein, to determine the organ type associated with the anatomical region, the processing circuitry is further configured to determine a presence of a shadow outline of an organ in the at least one contrast image.
12. The system of claim 11, wherein the processing circuitry is configured to determine the organ type as renal type in response to determining that shadow outline is present; and wherein the processing circuitry is configured to determine the organ type as hepatic type in response to determining that the shadow outline is absent.A0013531W00113. The system of any one of claims 1 to 12, wherein to perform the at least one action, the processing circuitry is configured to generate an output, an alert, or an indicator signal indicative of one or both of the organ type or the therapy program, the system further comprising a neuromodulation generator configured to:receive the indicator signal from the processing circuitry; andbased on the indicator signal, generate a therapy signal for delivery to a neuromodulation catheter configured to deliver neuromodulation therapy.
14. The system of claim 13, further comprising a neuromodulation catheter configured to be introduced in a blood vessel and deliver the neuromodulation therapy to the patient.
15. The system of claim 14, wherein the neuromodulation catheter comprises:an elongate body configured to transform from a relatively low profile configuration to an expanded configuration; anda therapy delivery element disposed on the elongate body and configured to deliver the neuromodulation therapy based on the therapy signal.
